Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury

Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury
Neuren Pharmaceuticals chief executive Jon Pilcher says the Kiwi firm is in a privileged position. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
Neuren Pharmaceuticals' boss Jon Pilcher says he was punching the air after leaving a recent successful meeting with the US Food and Drug Administration.Neuren, a local company which develops treatments for neurological disorders including Rett syndrome, has been cleared to begin phase-three trials for the drug NNZ-2591 to treat Phelan-McDermid syndrome. It will be the first-ever phase-three trial in children with the rare genetic condition.The disorders Neuren targets for treatment with its drugs are often debilitating and can ha...

More Markets

Ebos’ largest shareholder selling $949m worth of stock
Markets

Ebos’ largest shareholder selling $949m worth of stock

Sybos is selling $949 million worth of Ebos shares at an 8.80% discount.

Goodman Property expects more of the same
Property

Goodman Property expects more of the same

Stable property values helped the company report net profit after tax of $109.6m.

Australia standout in Mainfreight’s 'satisfactory' result
Infrastructure

Australia standout in Mainfreight’s 'satisfactory' result

New government depreciation rules won’t change its investment plans.

Trade Window sees ebitda breakeven for FY26
Markets

Trade Window sees ebitda breakeven for FY26

The company has shaved costs, grown revenue and benefited from trade turmoil.